Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

被引：25

作者：

Wechalekar, AD ^{[1
]}

Chen, CI ^{[1
]}

Sutton, D ^{[1
]}

Reece, D ^{[1
]}

Voralia, M ^{[1
]}

Stewart, AK ^{[1
]}

机构：

[1] Univ Toronto, Dept Hematol Oncol, Princess Margaret Hosp, Toronto, ON, Canada

来源：

LEUKEMIA & LYMPHOMA | 2003年 / 44卷 / 07期

关键词：

thalidomide; intermediate dose; dose escalation; efficacy;

D O I：

10.1080/1042819031000067918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide at doses >200mg has 100% grade 1-2 and 25% grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43% of patients responded with paraprotein decline >75% - 2 (6%), 50-75% - 7 (23%), 25-50% - 4 (14%) and 2 (6%) were stable. All five patients with 13q deletion responded. Only 54% reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17%) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.

引用

页码：1147 / 1149

页数：3

共 17 条

[1] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[2]

Bellamy WT, 1999, CANCER RES, V59, P728

[3]

Corral LG, 1999, J IMMUNOL, V163, P380

[4]

Durie BGM, 2001, BLOOD, V98, p163A

[5] Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J].

Geitz, H ;

Handt, S ;

Zwingenberger, K .

IMMUNOPHARMACOLOGY, 1996, 31 (2-3) :213-221

[6]

Grosbois B, 2001, BLOOD, V98, p163A

[7] Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].

Haslett, PAJ ;

Corral, LG ;

Albert, M ;

Kaplan, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892

[8] Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia [J].

Johnston, RE ;

Abdalla, SH .

LEUKEMIA & LYMPHOMA, 2002, 43 (02) :351-354

[9] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].

Juliusson, G ;

Celsing, F ;

Turesson, I ;

Lenhoff, S ;

Adriansson, M ;

Malm, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96

[10]

Kneller A, 2000, BRIT J HAEMATOL, V108, P391

← 1 2 →